Scientific Commons: J. P. Lalezari

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks (2005)

Trottier, B., Walmsley, S., Reynes, J., Piliero, P.J., O'Hearn, M., Nelson, M., ...

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. (2005)

Nelson, M., Arastéh, K., Clotet, B., Cooper, D.A., Henry, K., Katlama, C., ...

Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS (2002)

Boyer, D.S., Cowen, S.J., Danis, R.P., Diamond, J.G., Fish, R.H., Goldstein, D.A., ...

Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has (2002)

Boyer, D.S., Cowen, S.J., Danis, R.P., Diamond, J.G., Fish, R.H., Goldstein, D.A., ...

Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.

Cundy, K C, Petty, B G, Flaherty, J, Fisher, P E, Polis, M A, Wachsman, M, ...

The pharmacokinetics of cidofovir (HPMPC; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine) were examined at five dose levels in three phase I/II studies in a total of 42 human immunodeficiency...

Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.

Yuen, G J, Drusano, G L, Fletcher, C, Capparelli, E, Connor, J D, Lalezari, J P, ...

We examined the pharmacokinetics of ganciclovir in different populations of cytomegalovirus (CMV)-infected patients through the use of nonlinear mixed-effects modelling. As expected, patient weight...

Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay.

Chernoff, D N, Miner, R C, Hoo, B S, Shen, L P, Kelso, R J, Jekic-McMullen, D, ...

Quantification of cytomegalovirus (CMV) DNA in blood may aid in the identification of patients at highest risk for developing CMV disease, the evaluation of new therapeutics, and the prompt...